Karachi, Otsuka Pakistan Limited informed Pakistan Stock Exchange about the recommendations made by the board of directors in the meeting held at Karachi on August 31, 2021.
The agenda of the meeting was discussion of profit and loss account for Year ended June 30, 2021 which portrayed a profit of Rs. 386,331 with earnings per share 31.93 basic and diluted respectively.
Further, 15% payment of cash dividend, bonus shares and right shares was agreed.
Furthermore, the share transfer books of the company will remain closed from October 21, 2021 to October 27, 2021 (both days inclusive).
Otsuka Pakistan Limited was incorporated in Pakistan as a public limited company and commenced commercial production of Intravenous Solutions in September 1989 at its factory in Hub, Baluchistan.
The Company is engaged in the manufacturing, marketing and distribution of intravenous infusions and trading in pharmaceutical products, nutritional foods and medical equipment. The Company is an indirect subsidiary of Otsuka Pharmaceutical Company Limited, Japan. Therapeutic Drugs are Otsuka Pakistan’s second line of business; currently consist of Pletaal and Mucosta which are being imported in finished form from Korea.
The total numbers of shares are 12,100,000. The Earnings per share is 7.53 in 2020 which was (14.49) in 2019. The Profit after Taxation is 91,066,000 in 2020 which was 175,348,000 in 2019.